Loading clinical trials...
Loading clinical trials...
Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD
Conditions
Interventions
Oglemilast
Placebo
+2 more
Locations
47
United States
Forest Investigative Site
Birmingham, Alabama, United States
Forest Investigative Site
Phoenix, Arizona, United States
Forest Investigative Site
Tucson, Arizona, United States
Forest Investigative Site
Buena Park, California, United States
Forest Investigative Site
Encinitas, California, United States
Forest Investigative Site
Fullerton, California, United States
Start Date
May 5, 2008
Primary Completion Date
May 15, 2009
Completion Date
May 15, 2009
Last Updated
September 19, 2019
NCT06712563
NCT06831994
NCT02755974
NCT05087641
NCT05050591
NCT05913765
Lead Sponsor
Forest Laboratories
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions